<DOC>
	<DOCNO>NCT01653574</DOCNO>
	<brief_summary>The hypothesis clinical research study discover study drug Famitinib Malate shrink slow growth pretreated HER2-negative metastatic breast cancer .</brief_summary>
	<brief_title>A Study Famitinib Malate HER2-negative Metastatic Breast Cancer</brief_title>
	<detailed_description>Famitinib Malate tyrosine kinase inhibitor mainly target vascular endothelial growth factor receptor 2 ( VEGFR2 ) , anti-angiogenesis effect view preclinical test . The investigator ' phase I study show drug 's toxicity manageable recommend phase II dose 25 mg . The hypothesis clinical research study discover study drug Famitinib Malate shrink slow growth pretreated HER2-negative breast cancer . The safety Famitinib Malate also study . Patients physical state , symptom , change size tumor , laboratory finding obtain on-study help research team decide Famitinib Malate safe effective pretreated HER2-negative metastatic breast cancer patient .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>●≥ 18 ≤ 70 year age . ECOG performance status 01 . Women diagnose HER2negative breast cancer . HER2 define 0 1+ stain immunohistochemistry FISH/CISH negative gene amplification . Metastatic breast cancer , confirm histological analysis . Have fail last chemotherapy regimen , experience 2 regimen relapse metastatic setting . Pretreated anthracycline , taxanes capecitabine ( rational reason use capecitabine acceptable ) mandatory . Have fail least 1 endocrine therapy , HR positive . Duration last therapy ( chemotherapy , radiotherapy , target therapy operation ) 4 week ( Duration nitroso mitomycin 6 week ) . Have least one extracranial measurable site disease accord RECIST 1.1 criterion previously irradiate . Life expectancy 3 month . If patient brain meninges metastasis , lesion must control least 8 week . Adequate hepatic , renal , heart , hematologic function ( hemoglobin ≥ 90g/L , neutrophil ≥ 1.5×10^9/L , platelet ≥ 80×10^9/L , ALT ≤ 2.5 x upper limit normal ( ULN ) , AST ≤ 2.5 x ULN , serum bilirubin ≤ 1.5 x ULN , serum creatine ≤ 1.5 x ULN , creatinine clearance rate ≥ 50ml/min , PT , APTT ≤ 1.5 x ULN ) , serum cholesterol ≤ 1.25 x ULN , serum glycerin trilaurate ≤ 2.0 x ULN , LVEF ≥ low limit normal ( LLN ) . Negative serum urine pregnancy test take woman within 7 day inclusion . Sexually active woman childbearing potential must use medically acceptable form contraception ( include oral contraception , injectable implantable method , intrauterine device , properly use barrier contraception ) begin study 8 week last dose investigated drug . A woman childbearing potential define one biologically capable become pregnant . This include woman use contraceptive whose sexual partner either sterile use contraceptive . Written inform consent prior study specific screening procedure , understand patient right withdraw study time without prejudice . Pregnant lactating woman . Uncontrolled hypertension monodrug therapy ( ＞140/90 mm Hg ) ；ischemia myocardium （≥ grade 2） myocardial infarction；arrhythmia（≥ grade 2 , QTcF ＞ 480ms female patients） New York Heart Association Class III/IV . Abnormal thyroid function history drug intervention . Any factor influence usage oral administration . The cumulative dos doxorubicin epirubicin inclusion surpass 300 mg/m2 600 mg/m2 , respectively . Brain meningeal metastasis . Receiving therapy thrombolysis anticoagulation . Unhealed wound bone fracture . Urine protein ≥++ confirm ＞1.0 g 24h quantity . Previous present history pulmonary fibrosis , interstitial pneumonia , pneumoconiosis , radiation pneumonitis , drugrelated pneumonitis greatlyimpaired pulmonary function . Disability serious uncontrolled intercurrence infection . The active HBV HCV infection HBV DNA ≥10^4/ml . Acquired inherent immunodeficiency； HIV infection； organ transplantation history . Abuse alcohol drug . Have receive prior treatment VEGFR TKI ( Bevacizumab permit ) . History malignancy except cure basal cell carcinoma skin carcinoma insitu uterine cervix .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Famitinib Malate</keyword>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>HER-2 negative</keyword>
</DOC>